Jonathan Greer, MD, FACR, FACP

Patients with systemic lupus erythematosus receiving anifrolumab are more likely to achieve earlier, more frequent and longer low disease activity, compared with those taking placebo, according to data.

Despite guidelines recommending early and aggressive therapy in rheumatoid arthritis, disease-modifying antirheumatic drug adoption for older patients remains low, according to data published in ACR Open Rheumatology.